Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

PHASE3CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

August 20, 2024

Study Completion Date

August 20, 2024

Conditions
Advanced Prostate CancerMetastatic Prostate CancerLocally Advanced Prostate Cancer
Interventions
DRUG

Triptorelin pamoate (embonate) salt

Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.

Trial Locations (36)

Unknown

Affiliated Hospital of Hebei University, Baoding

Beijing Hospital, Beijing

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

Hunan Cancer Hospital, Changsha

West China Hospital of Sichuan University, Chengdu

Chongqing University Cancer Hospital, Chongqing

The First Affiliated Hospital of Chongqing Medical University, Chongqing

Deyang People's Hospital, Deyang

Sun Yat-Sen University Cancer Center, Guangzhou

Guizhou Provincial People's Hospital, Guiyang

The Affiliated Hospital of Guizhou Medical University, Guiyang

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Qilu Hospital of Shandong University, Jinan

Shandong Provincial Hospital, Jinan

Nanjing Drum Tower Hospital, Nanjing

Zhongda Hospital Southeast University, Nanjing

Ningbo First Hospital, Ningbo

Fudan University Shang Hai Cancer Center, Shanghai

Shanghai Fifth People's Hospital, Shanghai

Shanghai Tongji Hospital, Shanghai

Liaoning Cancer Hospital & Institute, Shenyang

The First Hospital of China Medical University, Shenyang

Peking University Shenzhen Hospital, Shenzhen

Suining Central Hospital, Suining

The Second Affiliated Hospital of Soochow University, Suzhou

Tianjin Cancer Hospital, Tianjin

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

The First Affiliated Hospital of Wannan Medical College, Wuhu

The Second Affiliated Hospital of Wannan Medical College, Wuhu

Wuxi People's Hospital, Wuxi

Northern Jiangsu People's Hospital, Yangzhou

Subei People's Hospital, Yangzhou

Yantai Yuhuangding Hospital, Yantai

Henan Cancer Hospital, Zhengzhou

Zigong First People's Hospital, Zigong

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT05590793 - Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate | Biotech Hunter | Biotech Hunter